CURRICULUM VITAE

Name: Ángel Raya Chamorro **Date of birth:** 23 November 1966
Nationality: Spanish
Working address: Bellvitge Biomedical Research Institute (IDIBELL)
Hospital Duran i Reynals, 3rd floor
Av. Gran Via 199-203
08908 Hospitalet de Llobregat (Barcelona) Spain
E-mail: araya@idibell.cat
URL: https://idibell.cat/en/research/area-medicina-regenerativa-english/regenerative-medicine-program/stem-cell-potency/
https://p-cmrc.cat/research/raya-group/
https://www.icrea.cat/Web/ScientificStaff/angel-raya--chamorro-354
https://www.ciber-bbn.es/grupos/grupo-de-investigacion?id=3618

Current position: ICREA Research Professor
Coordinator, Regenerative Medicine Program at IDIBELL
Director, Program for Translation of Regenerative Medicine in Catalonia (P-CMRC)

Education and Research Training:

1990	M.D., University of Valencia, Spain
1995	Ph.D. in Medicine and Surgery, University of Valencia, Spain
1995-2000	Postdoctoral fellow, IIC/FVIB, Valencia, Spain
2000-2004	Postdoctoral fellow, Salk Institute for Biological Studies, La Jolla, CA, USA

Professional Experience:

1991-1995	Predoctoral Fellow. Department of Physiology, University of Valencia, Spain. Supervisor: Joaquín Romá.
1994-1995	Special Project Associate. Peripheral Nerve Center, Department of Neurology, Mayo Clinic, Rochester, MN, USA. Supervisor: Phillip A. Low.
1995-1999	Postdoctoral Research Fellow. Molecular Pathology Unit. Instituto de Investigaciones Citológicas, FVIB. Valencia, Spain. Supervisor: Juan Saus.
1999-2000	Senior Research Associate. Molecular Pathology Unit. Instituto de Investigaciones Citológicas, FVIB. Valencia, Spain. Supervisor: Juan Saus.
2000-2004	Research Associate. Gene Expression Laboratory. Salk Institute for Biological Studies, La Jolla, CA, USA. Supervisor: Juan Carlos Izpisúa-Belmonte.
2004-2006	Senior Research Associate. Gene Expression Laboratory. Salk Institute for Biological Studies, La Jolla, CA, USA.
2006-present	ICREA Research Professor
2006-2009	Scientific Coordinator, Center of Regenerative Medicine in Barcelona, Barcelona, Spain.
2008-present:	Group Leader, Networking Center of Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
2010-2015:	Group Leader, Institute for Bioengineering of Catalonia, Barcelona Science Park, Barcelona, Spain.
2014-2019:	Director, Center of Regenerative Medicine in Barcelona, Barcelona, Spain.
2017-present	Director, Program for Translation of Regenerative Medicine in Catalonia (P-CMRC)
2020-present	Coordinator, Regenerative Medicine Program at Bellvitge Biomedical Research Institute (IDIBELL)

Teaching activities:

2016-2019	Assistant Professor, Pompeu Fabra University, Dept. Experimental Sciences, Barcelona, Spain.
1996	Assistant Professor. Department of Physiology, University of Valencia, Spain.

International and National Advisory Committees:

2011, 2020	Expert Commission Member, Biomedicine Panel, MICINN (Spanish Ministry of Science and Innovation)
2019	Panel Member, PERIS

2018, 2019 Chair, Medical Biotechnology Panel, Stimulus of Scientific Employment, Individual Support, FCT (Portuguese Agency for Grant Evaluation)
2018 Panel Member, International Research Agenda Programme, FNP (Foundation for Polish Science)
2018 Jury Member, Crioestaminal Award 10th Edition, Associação Viver a Ciência, Portugal
2017 Expert Commission Member, SAF-SP3 Commission, MICINN (Spanish Ministry of Science and Innovation)
2015-2020 Member, Scientific Evaluation Committee, Joint Transnational Calls (JTC) on Rare Diseases (E-Rare3, EJP RD)
2016 Adjunct, Integrated Projects of Excellence Panel, FIS (Spanish Health Research Fund)
2016 Jury Member, Crioestaminal Award 9th Edition, Associação Viver a Ciência, Portugal
2015 President, Integrated Projects of Excellence Panel, FIS (Spanish Health Research Fund)
2014 Expert Commission Member, Clinical Trials Panel, FIS (Spanish Health Research Fund)
2013-2014 Expert Member, Life & Health Sciences Panel, FCT (Portuguese Agency for Grant Evaluation)
2012-2016 Expert Commission Member, Biotechnology Panel, FIS (Spanish Health Research Fund)
2012 European Commission Expert Meeting. Invited participation at IMI's 8th Call Preparatory Workshop
2010-2014 Member of the Base Commission, Fundamental Biology Panel, ANEP (Spanish National Agency for Grant Evaluation)
2010 Member Evaluation Committee "Stem Cells Finalized Research", ANR (French Agency for Grant Evaluation)
2018 *Ad-hoc* Reviewer IFCAH (International Fund Congenital Adrenal Hyperplasia) Project grants
2018 *Ad-hoc* Reviewer Welsh Government's Sêr Cymru II Programme
2009-present *Ad-hoc* Reviewer AAECAU (Andalusian Agency for Grant Evaluation)
2009-present *Ad-hoc* Reviewer FCT (Portuguese Agency for Grant Evaluation)
2009 *Ad-hoc* Reviewer CRC (Canada Research Chair)
2009 *Ad-hoc* Reviewer FARF (Fanconi Anemia Research Fund)
2009 European Society of Human Reproduction and Embryology Medicine Expert Meeting. Invited participation at the Stem Cells Expert Meeting
2007-present *Ad-hoc* Reviewer AGAUR (Catalonian Agency for Grant Evaluation)
2007 European Commission Expert Meeting. Invited participation at the Brainstorming session on Regenerative Medicine Research
2006-present *Ad-hoc* Reviewer ANEP/AEI (Spanish National Agency for Grant Evaluation)

Honors and awards:

- "Medalla García-Blanco" Award for young researchers in biomedicine; Fundación Valenciana de Estudios Avanzados; Valencia 1994.
- "Premio de Honor Dr. Benaprés"; Sociedad Española de Medicina y Cirugía Cosmética; Sitges 2016
- "City of Barcelona" Award, Life Sciences Category; Ajuntament de Barcelona; 2019

Publications:

1. Escriba R, Larrañaga-Moreira JM, Richaud-Patin Y, Pourchet L, Lazis I, Jiménez-Delgado S, Morillas-García A, Ortiz-Genga M, Ochoa JP, Carreras D, Pérez GJ, de la Pompa JL, Brugada R, Monserrat L, Barriales-Villa R, **Raya A.** Modeling variable clinical presentation of familial hypertrophic cardiomyopathy with iPSC-derived cardiomyocytes. **Circ Res.** Under revision. RE: CIRCRES/2022/321951

2023

2. Tristán-Noguero A, Fernández-Carasa I, Calatayud C, Bermejo-Casadesús C, Pons-Espinal M, Colini-Baldeschi A, Campa L, Artigas F, Bortolozzi A, Domingo-Jiménez R, Ibáñez S, Pineda M, Artuch R, **Raya A**, García-Cazorla A, Consiglio A. iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation. **EMBO Mol Med**. In press. **IF ISI:** 14.26 PMID: N/A.

3. Siguero-Álvarez M, Salguero-Jiménez A, Grego-Bessa J, de la Barrera J, MacGrogan D, Prados B, Sánchez-Sáez F, Felipe-Medina N, Torroja C, Sabater-Molina M, Escribá R, Richaud-Patin Y, Iglesias-García O, Sbroggio M, Calleja S, Dopazo A, Ibañez B, Monserrat L, Pérez-Pomares JM, Sánchez-Cabo F, Pendas AM, **Raya A**, Gimeno-Blanes JR, de la Pompa JL. (2023) A human hereditary cardiomyopathy shares a genetic substrate with bicuspid aortic valve. **Circulation** 147:47-65. **IF ISI:** 29.69 PMID: 36325906

2022

4. Pesce M, Duda G, Forte G, Girao H, **Raya A**, Roca-Cusachs P, Sluijter J, Tschöpe C, Van Linthout S. Cardiac fibroblasts and mechanosensation: inseparably tied in heart development, health and disease. **Nat Rev Cardiol.** doi: 10.1038/s41569-022-00799-2. **IF ISI:** 49.42 PMID: 36376437.
5. Alvarez-Palomo B, Veiga A, **Raya A**, Codinach M, Torrents S, Ponce Verdugo L, Rodriguez-Aierbe C, Cuellar L, Alenda R, Arbona C, Hernández-Maraver D, Fusté C, Querol S. (2022) Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells. **Stem Cell Res Ther**, 13:408. **IF ISI:** 8.079. PMID: 35962457
6. Dajani R, Jiwani B, Carvalho AS, Caulfield T, de Melo H, Ghaly M, Ilkilic I, Nanji A, Neves M, **Raya A**, Zoloth L, Carter R, Matar M, Rendas A, Surani A, Rossant J, Kriegstein A, Lalani E-N. (2022) Diversifying stem cell debates: Including Muslim contexts and perspectives. **Stem Cell Rep**, 17:1019-1022. **IF ISI:** 7.765. PMID: 35395176
7. Mazuelas H, Magallón-Lorenz M, Fernandez-Rodriguez J, Uriarte I, Richaud-Patin Y, Terribas E, Villanueva A, Castellanos E, Blanco I, **Raya A**, Chojnacki J, Heyn H, Romagosa C, Lázaro C, Gel B, Carrió M, Serra E. (2022) Modeling iPSC-derived human neurofibroma-like tumors in mice uncover the heterogeneity of Schwann cells within plexiform neurofibromas. **Cell Rep**, 38:110385. **IF ISI:** 9.423. PMID: 35172160

2021

8. Iborra-Egea O, Martínez-Falguera D, Roura S, Bayes-Genis A, **Raya A**, Gálvez-Montón C. (2021) Porcine iPSC generation: Testing different protocols to a successful application. **Methods Mol Biol**, doi: 10.1007/7651_2021_446. **IF ISI:** 1.17. PMID: 34845658
9. Sánchez-Botet A, Quandt E, Masip N, Escribá R, Novellasdemunt L, Gasa L, Li VSW, **Raya A**, Clotet J, Ribeiro MPC. (2021) The atypical cyclin P regulates cancer cell stemness through activation of the WNT pathway. **Cell Oncol (Dordr)**, 44:1273-86. **IF ISI:** 6.730. PMID: 34604945
10. Duarri A, Rodríguez-Bocanegra E, Martínez-Navarrete G, Biarnés M, García M, Ferraro LL, Kuebler B, Aran B, Izquierdo E, Aguilera-Xiol E, Casaroli-Marano RP, Trias E, Fernandez E, **Raya A**, Veiga A, Monés J. (2021) Transplantation of human induced pluripotent stem cell-derived retinal pigment epithelium in a swine model of geographic atrophy. **Int J Mol Sci,** 22:10497. **IF ISI:** 4.556. PMID: 34638840
11. Ferrer-Lorente R, Lozano-Cruz T, Fernández-Carasa I, Miłowska K, de la Mata FJ, Bryszewska M, Consiglio A, Ortega P, Gómez R, **Raya A**. (2021) Cationic carbosilane dendrimers prevent abnormal alpha-synuclein accumulation in Parkinson's disease patient-specific dopamine neurons. **Biomacromolecules,** 22:4582-91. **IF ISI:** 6.988. PMID: 34613701
12. Ruiz de Garibay G, Fernandez-Garcia I, Mazoyer S, Leme de Calais F, Ameri P, Martinez-Ruiz SH, Damiola F, Barjhoux L, Thomassen M, Andersen LVB, Herranz C, Mateo F, Palomero L, Espin R, Gómez A, García N, Jimenez D, Bonifaci N, Extremera AI, Castaño J, **Raya A**, Eyras E, Puente XS, Brunet J, Lázaro C, Gemo, Cimba, Radice P, Barnes DR, Antoniou AC, Spurdle AB, de la Hoya M, Baralle D, Barcellos-Hoff MH, Pujana MA. (2021) Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. **Hum Mutat,** 42:1488-1502. **IF ISI:** 4.878. PMID: 34420246
13. Escriba R, Ferrer-Lorente R, **Raya A**. (2021) Inborn errors of metabolism: Lessons from iPSC models. **Rev Endocr Metab Disord,** 22:1189-200. **IF ISI:** 5.516. PMID: 34241766
14. Carola G, Malagarriga D, Calatayud C, Pons-Espinal M, Blasco-Agell L, Richaud-Patin Y, Fernandez-Carasa I, Baruffi V, Beltramone S, Molina E, Dell'Era P, Toledo-Aral JJ, Tolosa E, Muotri AR, Garcia Ojalvo J, Soriano J*, **Raya A*,** Consiglio A*. (2021) Parkinson's disease patient-specific neuronal

networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration. ***npj* Parkinsons Dis,** 7:55. **IF ISI:** 8.651. PMID: 34215735

15. Alvarez-Palomo B, García-Martinez I, Gayoso J, **Raya A**, Veiga A, Abad ML, Eiras A, Guzmán-Fulgencio M, Luis-Hidalgo M, Eguizabal C, Santos S, Balas A, Alenda R, Sanchez-Gordo F, Verdugo LP, Villa J, Carreras E, Vidal F, Madrigal A, Herrero MJ, Rudilla F, Querol S. (2021) Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells. **Stem Cell Res Ther,** 12:233. **IF ISI:** 5.116. PMID: 33849662
16. Mateos-Aierdi AJ, Dehesa-Etxebeste M, Goicoechea M, Aiastui-Pujana A, Richaud-Patin Y, Jimenez-Delgado S, **Raya A**, Naldaiz-Gastesi N, Lopez de Munain A. (2021) Patient-specific iPSC-derived cellular models of LGMDR1**. Stem Cell Res,** 53:102333. **IF ISI:** 4.495. PMID: 33862537
17. Salas A, Duarri A, Fontrodona L, Ramirez DM, Badia A, Isla-Magrane H, Ferreira-de-Souza B, Zapata MA, **Raya A**, Veiga A, Garcia-Arumi J. (2021) Cell therapy with human induced pluripotent stem cell-derived retinal pigment epithelium and retinal precursor cells prevents visual function loss in a rat model of retinal degeneration, **Mol Ther Methods Clin Dev**, 20:688-702. **IF ISI:** 4.533. PMID: 33738324
18. Tadevosyan K, Iglesias-Garcia O, Mazo MM, Prosper F, **Raya A**. (2021) Engineering and assessing cardiac tissue complexity. **Int J Mol Sci,** 22:1479. **IF ISI:** 4.556. PMID: 33540699

2020

19. Casanova JD, González-Carrillo J, Martín-Jiménez J, Cuenca-Muñoz J, Muñoz-Esparza C, Siguero-Alvarez M, Escriba, R, Burillo-Milla E, de la Pompa JL, **Raya A**, Gimeno JR, Sabater-Molina M, Bernabé-García G. (2020) Trabeculated myocardium in Hypertrophic Cardiomyopathy: Clinical consequences. **J Clin Med**, 9, 3171; doi:10.3390/jcm9103171. **IF ISI:** 3.303. PMID: 33007916.
20. Benzoni P, Campostrini G, Bertini V, Marchina E, Iascone M, Ahlberg G, Olesen MS, Crescini E, Mora C, Bisleri G, Muneretto C, Ronca R, Presta M, Poliani PL, Piovani G, Verardi R, Di Pasquale E, Consiglio A, **Raya A**, Baruscotti M, DiFrancesco D, Memo M, Barbuti A, Dell'Era P. (2020) Human iPSC modeling of a familial form of atrial fibrillation reveals a gain of function of If and ICaL in patient-derived cardiomyocytes. **Cardiovasc Res,** 116:1147-60. **IF ISI:** 7.014. PMID: 31504264
21. Veiga A, Aran B, **Raya A**, Messinis I, Mahmood T. (2020) EBCOG position statement: ethics of stem cell research. **Eur J Obstet Gynecol Reprod Biol,** pii: S0301-2115(20)30025-7. doi: 10.1016/j.ejogrb.2020.01.017. **IF ISI:** 2.024. PMID: 32007341

2019

22. Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, **Raya A**, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. (2019) Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. **J Clin Invest**, 129(10):4539-49. **IF ISI:** 12.282. PMID: 31524631.
23. Castaño J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Mosquera JL, Blanco E, Wang X, Prieto C, Zabaleta L, Mereu E, Rovira M, Jiménez-Delgado S, Matson DR, Heyn H, Bresnick EH, Gottgens B, Di Croce L, Menendez P, **Raya A**, Giorgetti A. (2019) GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. **Stem Cell Rep**, 13(3):515-529. **IF ISI:** 5.499. PMID: 31402335
24. Fernández-Santiago R, Merkel A, Castellano G, Heath S, **Raya A**, Tolosa E, Martí MJ, Consiglio A, Ezquerra M. (2019) Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients. **Clin Epigenetics,** 11:108. doi: 10.1186/s13148-019-0701-6. **IF ISI:** 5.496. PMID: 31337434
25. Garcia-Puig A, Mosquera, JL, Jimenez-Delgado S, Garcia-Pastor C, Jorba I, Navajas D, Canals F, **Raya A**. (2019) Proteomics analysis of extracellular matrix remodeling during zebrafish heart regeneration. **Mol Cell Proteomics**, 18:1745-55. **IF ISI:** 4.828. PMID: 31221719
26. Valls-Margarit M, Iglesias-García O, Di Guglielmo C, Sarlabous L, Paoli R, Comelles J, Blanco D, Jimenez-Delgado S, Castillo-Fernández O, Samitier J, Jané R, Martínez E, **Raya A**. (2019) Engineered macroscale cardiac constructs elicit human myocardial tissue-like functionality. **Stem Cell Rep**, 13:207-20. **IF ISI:** 5.499. PMID: 31231023

27. Uroz M, Garcia-Puig A, Tekeli I, Elosegui-Artola A, Albertazzi L, Roca-Cusachs P, **Raya A**, Trepat X. (2019) Traction forces at the cytokinetic ring regulate cell division and polyploidy in the migrating zebrafish epicardium. **Nat Mat,** 18:1015-23. **IF ISI:** 38.887. PMID: 31160803
28. Calatayud C, Carola G, Fernández-Carasa I, Valtorta M, Jiménez-Delgado S, Díaz M, Soriano-Fradera J, Cappelletti G, García-Sancho J, **Raya A***, Consiglio C* (2019) CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons. **Sci Rep,** 9:6811. **IF ISI:** 4.011. PMID: 31048719
29. Saludas L, Garbayo E, Mazo M, Pelacho B, Abizanda G, Iglesias Garcia O, **Raya A**, Prosper F, Blanco-Prieto MJ (2019) Long-term engraftment of human cardiomyocytes combined with biodegradable microparticles induces heart repair. **J Pharmacol Exp Ther,** 370:761-71. **IF ISI:** 3.615. PMID: 30728248
30. Cutrale F, Rodriguez D, Hortigüela V, Chiu C-L, Otterstrom J, Mieruszynski S, Seriola A, Larrañaga E, **Raya A**, Lakadamyali M, Fraser SE, Martinez E, Ojosnegros S (2019) Using enhanced Number and Brightness to measure protein aggregation dynamics in live cells. **Nat Protoc**, 14:616-38. **IF ISI:** 11.334. PMID: 30675035
31. Carrió M, Mazuelas H, Richaud-Patin Y, Gel B, Terribas E, Rosas I, Jimenez-Delgado S, Biayna J, Vendredy L, Blanco I, Castellanos E, Lázaro C, **Raya A***, Serra E* (2019) Reprogramming captures the genetic and tumorigenic properties of Neurofibromatosis Type 1 plexiform neurofibromas. **Stem Cell Rep**, 12:411-26. **IF ISI:** 5.499. PMID: 30713041
32. di Domenico A, Carola G, Calatayud C, Muñoz JP, Faella A, Richaud-Patin Y, Soriano J, Ferrer I, Tolosa E, Zorzano A, Cuervo AM, **Raya A***, Consiglio A* (2019) Patient-specific iPSC-derived astrocytes contribute to non-cell autonomous neurodegeneration in Parkinson's disease. **Stem Cell Rep**, 12:213-29. **IF ISI:** 5.499. PMID: 30639209

2018

33. Buning H, Griesenbach U, Fehse B, Yla-Herttuala S, Anagnou NP, van Beusechem V, **Raya A**, Verhoeyen E (2018) Consensus statement of European Societies of Gene and Cell Therapy on the reported birth of genome-edited babies in China. **Hum Gene Ther,** 29:1337-8. **IF ISI:** 3.855. PMID: 30511888
34. Olgasi C, Talmon M, Ranaldo G, Merlin S, Richaud-Patin Y, Lombardo A, Colangelo D, di Scipio F, Berta GN, Valeri F, Naldini L, Messina M, Schinco P, **Raya A**, Follenzi A (2018) Patient-specific iPSC-derived endothelial cells provide long-term phenotypic correction of hemophilia A. **Stem Cell Rep**, 11:1391-1406. **IF ISI:** 5.499. PMID: 30416049
35. Suh H, Zhou Q-G, Fernandez-Carasa I, Clemenson GD Jr, Pons-Espinal M, Ro EJ, Marti M, **Raya A**, Gage FH, Consiglio A (2018) Long-term labeling of hippocampal neural stem cells by a lentiviral vector. **Front Mol Neurosci**, 11, 415. **IF ISI:** 3.720. PMID: 30498432
36. Tolosa E, Botta-Orfila T, Morató X, Calatayud C, Ferrer-Lorente R, Martí MJ, Fernandez M, Gaig C, **Raya A**, Consiglio A, Ezquerra M, Fernández-Santiago R. (2018) MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. **Neurobiol Aging**, 69:283-291. **IF ISI:** 4.398. PMID: 29935433
37. Parga JA, García-Garrote M, Martínez S, **Raya A**, Labandeira-García JL, Rodríguez-Pallares J. (2018) Prostaglandin EP2 receptors mediate mesenchymal stromal cell-neuroprotective effects on dopaminergic neurons. **Mol Neurobiol**, 55:4763-76. **IF ISI:** 4.586. PMID: 28717970
38. Notari M, Ventura-Rubio A, Bedford-Guaus SJ, Jorba I, Mulero L, Navajas D, Martí M, **Raya A**. (2018) The local microenvironment limits the regenerative potential of the mouse neonatal heart. **Sci Adv**, 4:eaao5553. **IF ISI:** 12.804. PMID: 29732402
39. Fontcuberta-PiSunyer M, Cervantes S, Miquel E, Mora-Castilla S, Laurent LC, **Raya** A, Gomis R, Gasa R. (2018) Modulation of the endocrine transcriptional program by targeting histone modifiers of the H3K27me3 mark. **Biochim Biophys Acta**, 1861:473-80. **IF ISI:** 4.599. PMID: 29530603
40. Matamoros-Angles A, Gayosso LM, Richaud-Patin Y, di Domenico A, Vergara C, Hervera A, Sousa A, Fernández-Borges N, Consiglio A, Gavín R, Lopez de Maturana R, Ferrer I, López de Munain A, **Raya A***, Castilla J*, Sánchez-Pernaute R*, del Río JA*. (2018) iPS cell cultures from a Gerstmann-Sträussler-Scheinker patient with the Y218N PRNP mutation recapitulate Tau pathology. **Mol Neurobiol**, 55:3033-48. **IF ISI:** 4.586. PMID: 28466265

41. Kim H, Calatayud C, Guha S, Fernández-Carasa I, Berkowitz L, Carballo-Carbajal I, Ezquerra M, Fernández-Santiago R, Kapahi P, **Raya Á**, Miranda-Vizuete A, Lizcano JM, Vila M, Caldwell KA, Caldwell GA, Consiglio A, Dalfo E. (2018) The small GTPase RAC1/CED-10 is essential in maintaining dopaminergic neuron function and survival against α-synuclein-induced toxicity. **Mol Neurobiol,** 55:7533-52. **IF ISI:** 4.586. PMID: 29429047

2017

42. Ojosnegros S, Cutrale F, Rodríguez D, Otterstrom JJ, Chiu C, Hortiguela V, Tarantino C, Seriola A, Mieruszynski S, Martinez E, Lakadamyali M, **Raya A***, Fraser SE*. (2017) Eph-ephrin signaling modulated by polymerization and condensation of receptors. **Proc Natl Acad Sci USA**, 114(50):13188-93. **IF ISI**: 9.661. PMID: 29192024
43. Kuebler B, Aran B, Miquel-Serra L, Muñoz Y, Ars E, Bullich G, Furlano M, Torra R, Marti M, Veiga A, Raya A. (2017) Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport Syndrome (ARAS). **Stem Cell Res**, 25:1-5. **IF ISI:** 3.902. PMID: 29246570
44. Kuebler B, Aran B, Miquel-Serra L, Muñoz Y, Ars E, Bullich G, Furlano M, Torra R, Marti M, Veiga A, Raya A. (2017) Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport Syndrome (XLAS). **Stem Cell Res**, 25:291-5. **IF ISI:** 3.902. PMID: 29150092
45. Martorell L, Luce E, Vazquez JL, Richaud-Patin Y, Jimenez-Delgado S, Corrales I, Borras N, Casacuberta-Serra S, Weber A, Parra R, Altisent C, Follenzi A, Dubart-Kupperschmitt A*, **Raya A***, Vidal F*, Barquinero J*. (2017) Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA. **J Thromb Haemost**, 15(11):2188-97. **IF ISI:** 4.899. PMID: 28834196
46. Gálvez-Montón C, Soler-Botija C, Iborra-Egea O, Díaz-Güemes I, Martí M, Iglesias-García O, Prat-Vidal C, Crisóstomo V, Llucià-Valldeperas A, Perea-Gil I, Roura S, Sánchez-Margallo FM, **Raya A**, Bayes-Genis A. (2017) Preclinical safety evaluation of allogeneic iPS cell-based therapy in a swine model of myocardial infarction. **Tissue Eng Part C Methods**, 23:736-44. **IF ISI:** 2.638. PMID: 28699384
47. Pulecio J, Verma N, Mejía-Ramírez E, Huangfu D, **Raya A**. (2017) CRISPR/Cas9-based engineering of the epigenome. **Cell Stem Cell**, 21:431-47. **IF ISI**: 23.394. PMID: 28985525
48. Calatayud C, Carola G, Consiglio A, **Raya A**. (2017) Modeling the genetic complexity of Parkinson's disease by targeted genome edition in iPS cells. **Curr Opin Genet Dev**, 46:123-131. **IF ISI**: 5.825. PMID: 28759872
49. Miquel-Serra L, Duarri A, Muñoz Y, Kuebler B, Aran B, Costa C, Martí M, Comabella M, Malhotra S, Montalban X, Veiga A, **Raya A**. (2017) Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. **Stem Cell Res**, 24:155-9. **IF ISI:** 3.902. PMID: 29034884
50. Tekeli I, Garcia-Puig A, Notari M, García-Pastor C, Aujard I, Jullien L, **Raya A**. (2017) Fate predetermination of cardiac myocytes during zebrafish heart regeneration. **Open Biol**, 7. pii: 170116. doi: 10.1098/rsob.170116. **IF ISI:** 3.890. PMID: 28659386
51. Bedford-Guaus S, Kim S, Mulero L, Vaquero JM, Morera C, Adan-Milanès R, Veiga A, **Raya A.** (2017) Molecular markers of putative spermatogonial stem cells in the domestic cat. **Reprod Domest Anim,** 52:177-186. **IF ISI:** 1.638. PMID: 28402059
52. Navarro S, Giorgetti A, **Raya A**, Tolar J. (2017) Induced pluripotency and gene editing in Fanconi anemia**. Curr Gene Ther**, 16:321-328. **IF ISI:** 2.218. PMID: 28103772

2016

53. Bedford-Guaus SJ, Chauvigné F, Mejía-Ramírez E, Martí M, Ventura-Rubio A, **Raya Á***, Cerdà J*, Veiga A*. (2016) Expression of the T85A mutant of zebrafish aquaporin 3b improves post-thaw survival of cryopreserved early mammalian embryos. **Zygote,** 24(6):839-847. **IF ISI:** 1.114. PMID: 27702419
54. Pulecio J, Alejo-Valle O, Capellera-Garcia S, Vitaloni M, Rio P, Mejía-Ramírez E, Caserta I, Bueren JA, Flygare J**, Raya A**. (2016) Direct conversion of fibroblasts to megakaryocyte progenitors. **Cell Rep** 17(3):671-683. **IF ISI**: 8.282. PMID: 27732845
55. Tekeli I, Aujard I, Trepat X, Jullien L, **Raya A***, Zalvidea D*. (2016) Long-term in vivo single cell lineage tracing of deep structures using three-photon activation. **Light Sci Appl,** 5: e16084. **IF ISI**: 14.098. PMID: 30167169

56. Capellera-Garcia S, Pulecio J, Dhulipala K, Siva K, Rayon-Estrada V, Singbrant S, Sommarin MNE, Walkley CR, Soneji S, Karlsson G, **Raya A**, Sankaran VG and Flygare J. (2016) Defining the minimal factors required for erythropoiesis through direct lineage conversion. **Cell Rep,** 15(11):2550-62. **IF ISI**: 8.282. PMID: 27264182
57. Vassena R, Heindryckx B, Peco R, Pennings G, **Raya A**, Sermon K, Veiga A. (2016) Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells. **Hum Reprod Update,** 22:411-9. **IF ISI**: 11.748. PMID: 26932460
58. Prieto J, León M, Ponsoda X, Sendra R, Bort R, Ferrer-Lorente R, **Raya A,** López-García C, Torres J. (2016) Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming. **Nat Commun,** 7:11124. **IF ISI**: 12.124. PMID: 27030341
59. Riera M, Fontrodona L, Albert S, Ramirez DM, Seriola A, Salas A, Muñoz Y, Ramos D, Villegas-Perez MP, Zapata MA, **Raya A**, Ruberte J, Veiga A, Garcia-Arumi J. (2016) Comparative study of human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) as a treatment for retinal dystrophies. **Mol Ther Methods Clin Dev,** 3: 16010. **IF ISI:** 3.681. PMID: 27006969

2015

60. Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Vilarrasa-Blasi R, Sánchez-Pla A, Mosquera JL, Soriano J, López-Barneo J, Canals JM, Alberch J, **Raya Á**, Vila M, Consiglio A, Martín-Subero JI, Ezquerra M, Tolosa E. (2015) Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients. **EMBO Mol Med,** 7:1529-46. **IF ISI**: 9.249. PMID: 26516212
61. Canals I, Soriano J, Orlandi JG, Torrent R, Richaud-Patin Y, Jiménez-Delgado S, Merlin S, Follenzi A, Consiglio A, Vilageliu L, Grinberg D, **Raya A**. (2015) Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks. **Stem Cell Rep,** 5: 546-57. **IF ISI**: 7.338. PMID: 26411903
62. Gálvez-Montón C, Fernandez-Figueras MT, Martí M, Soler-Botija C, Roura S, Perea-Gil I, Prat-Vidal C, Llucià-Valldeperas A, **Raya Á**, Bayes-Genis A. (2015) Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts. **Stem Cell Res Ther,** 6:108. doi: 10.1186/s13287-015-0101-6. **IF ISI:** 4.504. PMID: 26205795
63. Torrent R, De Angelis Rigotti F, Dell'Era P, Memo M, **Raya A***, Consiglio A*. (2015) Using iPS cells toward the understanding of Parkinson's disease. **J Clin Med,** 4: 584-566. **IF ISI:** 5.583. PMID: 26239346
64. Martorell L, Corrales I, Ramirez L, Parra R, **Raya A**, Barquinero J, Vidal F. (2015) Molecular characterization of ten F8 splicing mutations in RNA isolated from patient's leucocytes: assessment of in silico prediction tools accuracy. **Haemophilia,** 21: 249-251. **IF ISI:** 3.569. PMID: 25652415
65. Notari M, Pulecio J, **Raya A**. (2015) Update on the Pathogenic Implications and Clinical Potential of microRNAs in Cardiac Disease. **BioMed Res Int,** 2015:105620. doi: 10.1155/2015/105620. **IF ISI:** 2.476. PMID: 26221581

2014

66. Andrades JA, Becerra J, Muñoz-Chápuli R, Martinez S, **Raya A**, Garcia-Sancho J, Moraleda JM. (2014) Stem cells therapy for regenerative medicine: Principles of present and future practice. **J Biomed Sci Eng,** 7:49-57. doi:10.4236/jbise.2014.72008 **IF ISI:** N/A. PMID: N/A
67. Navarro S, Moleiro V, Molina-Estevez FJ, Lozano ML, Chinchon R, Almarza E, Quintana-Bustamante O, Mostoslavsky G, Maetzig T, Galla M, Heinz N, Schiedlmeier B, Torres Y, Modlich U, Samper E, Segovia JC, **Raya A**, Güenechea G, Izpisua Belmonte JC, Bueren JA. (2014) Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: Implications in cell reprogramming and stem cell therapy. **Stem Cells,** 32:436-46. **IF ISI:** 5.902. PMID: 24420904

2013

68. Sanchez-Danes A, Benzoni P, Memo M, Dell'Era P, **Raya A***, Consiglio A*. (2013) Induced pluripotent stem cell-based studies of Parkinson's disease: challenges and promises. **CNS Neurol Disord Drug Targets,** 12:1114-27. **IF ISI:** 2.702. PMID: 24040813

69. Orenstein S, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig L, Dauer W, Consiglio A, **Raya A**, Sulzer D, Cuervo A. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. **Nat Neurosci,** 16:394-406. **IF ISI**: 16.095. PMID: 23455607

2012

70. McLenachan S, Menchon C, **Raya A**, Consiglio A, Edel MJ. (2012) Cyclin A1 is essential for setting the pluripotent state and reducing tumorigenicity of induced pluripotent stem cells. **Stem Cells Dev,** 21:2891-9. **IF ISI:** 4.670. PMID: 22500553
71. Sanchez-Danés A, Richaud Y, Carballo-Carbajal I, Jiménez S, Caig C, Mora S, di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, **Raya A**. (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. **EMBO Mol Med,** 4:380-395. **IF ISI:** 10.333. PMID: 22407749
72. Fütterer A, **Raya A**, Llorente M, Izpisua Belmonte JC, de la Pompa J, Klatt P, Martinez AC. (2012) Ablation of Dido3 compromises lineage commitment of stem cells in vitro and during early embryonic development. **Cell Death Differ,** 19:132-43. **IF ISI:** 8.385. PMID: 21660050
73. Sanchez-Danes A, Consiglio A, Richaud Y, Rodriguez-Pisa I, Dehay B, Edel M, Bove J, Memo M, Vila M, **Raya A**. (2012) Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and iPS cells. **Hum Gene Ther,** 23:56-69. **IF ISI:** 4.019. PMID: 21877920

2011

74. Woods NB, Parker A, Moraghebi R, Lutz M, Firth A, Brennand K, Berggren W, **Raya A**, Izpisua Belmonte JC, Gage F, Verma I. (2011) Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. **Stem Cells,** 29:1158-64. **IF ISI:** 7.701. PMID: 21544903

2010

75. Bayes-Genis A, Soler-Botija C, Farré J, Sepúlveda P, **Raya A**, Roura S, Prat-Vidal C, Gálvez-Montón C, Montero JA, Büscher D, Izpisúa Belmonte JC. (2010) Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents**. J Mol Cell Cardiol,** 49:771-80. **IF ISI:** 5,499. PMID: 20713059
76. Santamaria P, Rogriguez-Piza I, Clemente-Casares X, Yamanouchi J, Mulero-Perez L, Aasen T, **Raya A**, Izpisua Belmonte JC. (2010) Turning human epidermis into pancreatic endoderm. **Rev Diabet Stud,** 7:158-67. **IF:** 2.553. PMID: 21060974
77. Sleep E, Boué S, Jopling C, Raya M, **Raya A**, Belmonte JC. (2010) Transcriptomics approach to investigate zebrafish heart regeneration. **J Cardiovasc Med,** 11(5):369-80. PMID: 20179605
78. Aran B, Rodríguez-Pizà I, **Raya A**, Consiglio A, Muñoz Y, Barri PN, Izpisúa JC, Veiga A. (2010) Derivation of human embryonic stem cells at the Center of Regenerative Medicine in Barcelona. **In Vitro Cell Dev Biol Anim,** 46:356-66. **IF ISI:** 1.312. PMID: 20177997
79. **Raya A**, Rodríguez-Pizà I, Navarro S, Richaud-Patin Y, Guenechea G, Sánchez-Danés A, Bueren J, Izpisúa-Belmonte JC. (2010) A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. **Nat Protoc,** 5:647-60. **IF ISI:** 8.362. PMID: 20224565
80. Jopling C, Sleep E, Raya M, Martí M, **Raya A**, Belmonte JC. (2010) Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. **Nature,** 464:606-9. **IF ISI:** 36.104. PMID: 20336145
81. Edel MJ, Menchon C, Menendez S, Consiglio A, **Raya A**, Belmonte JC. (2010) Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. **Genes Dev,** 24:561-73. **IF ISI:** 12.889. PMID: 20231315
82. Mizrak SC, Chikhovskaya JV, Sadri-Ardekani H, van Daalen S, Korver CM, Hovingh SE, Roepers-Gajadien HL, **Raya A**, Fluiter K, de Reijke T, de la Rosette J, Knegt AC, Belmonte JC, van der Veen F, de Rooij D, Repping S, van Pelt A. (2010) Embryonic stem cell-like cells derived from adult human testis. **Hum Reprod,** 25:158-67. **IF ISI:** 4.475. PMID: 19815622

2009

83. Rodríguez-Pizà I, Richaud-Patin Y, Vassena R, González F, Barrero MJ, Veiga A, **Raya A**, Izpisua-Belmonte JC. (2009) Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. **Stem Cells,** 28:36-44. PMID: 19890879
84. Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodríguez-Pizà I, Vassena R, **Raya A**, Boué S, Barrero MJ, Corbella BA, Torrabadella M, Veiga A, Belmonte JC. (2009) Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. **Cell Stem Cell,** 5:353-7. **IF ISI:** 23.563. PMID: 19796614
85. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, **Raya A**, Wahl GM, Belmonte JC. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. **Nature,** 460:1140-4. **IF ISI:** 34.480. PMID: 19668186
86. **Raya A**, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ, Consiglio A, Castella M, Rio P, Sleep E, Gonzalez F, Tiscornia G, Garreta E, Aasen T, Veiga A, Verma IM, Surralles J, Bueren J, Belmonte, JC. (2009) Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. **Nature,** 460:53-9. **IF ISI:** 34.480. PMID: 19483674
87. **Raya A**, Izpisua-Belmonte, JC. (2009) Stem cell research in Spain: if only they were windmills.... **Cell Stem Cell**, 4, 483-6. PMID: 19497274

2008

88. Aasen T, **Raya A**, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilić J, Pekarik V, Tiscornia G, Edel M, Boué S, Izpisúa Belmonte JC. (2008) Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. **Nat Biotechnol,** 26:1276-84. **IF ISI:** 22.297. PMID: 18931654
89. **Raya A**, Izpisúa Belmonte JC. (2008) Insights into the establishment of left-right asymmetries in vertebrates. **Birth Defects Res C Embryo Today,** 84:81-94. PMID: 18546333
90. **Raya A**, Rodríguez-Pizà I, Arán B, Consiglio A, Barri PN, Veiga A, Izpisúa Belmonte JC. (2008) Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts. **Cold Spring Harb Symp Quant Biol,** 73:127-35. PMID: 19028986

2007

91. Ribeiro I, Kawakami Y, Büscher D, **Raya A**, Rodríguez-León J, Morita M, Rodríguez Esteban C, Izpisúa Belmonte JC. (2007) Tbx2 and Tbx3 regulate the dynamics of cell proliferation during heart remodeling. **PLoS One,** 25;2(4):e398. PMID: 17460765
92. Matsui T, **Raya A**, Callol C, Kawakami Y, Oishi I, Rodriguez-Esteban C, Izpisua Belmonte JC. (2007) Miles-apart-mediated regulation of cell-Fibronectin interaction and myocardial migration in zebrafish. **Nat Clin Pract Cardiovasc Med,** 48(Suppl 1):S77-82. PMID: 17230219

2006

93. Oishi I, Kawakami Y, **Raya A**, Callol-Massot C, Izpisua Belmonte JC. (2006) Regulation of primary cilia formation and left-right patterning in zebrafish by a noncanonical Wnt signaling mediator. **Nat Genet,** 38:1316-22. PMID: 17013396
94. Suzuki A, **Raya A**, Kawakami Y, Morita M, Matsui T, Nakashima K, Gage FH, Rodriguez-Esteban C, Izpisua Belmonte JC. (2006) Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. **Proc Natl Acad Sci USA,** 103:10294-9. PMID: 16801560
95. **Raya A**, Izpisua Belmonte JC. (2006) Left-right in the vertebrate embryo: from early information to higher-level integration. **Nat Rev Genet,** 7:283-93. PMID: 16543932
96. Suzuki A, **Raya A**, Kawakami Y, Morita M, Matsui T, Nakashima K, Gage FH, Rodriguez-Esteban C, Izpisua Belmonte JC. (2006) Maintenance of embryonic stem cell pluripotency by Nanog-mediated reversal of mesoderm specification. **Nat Clin Pract Cardiovasc Med,** 3(Suppl 1):S114-S122. PMID: 16501617

2005

97. Merki E, Zamora M, **Raya A**, Kawakami Y, Zhang X, Burch J, Kubalak S, Kaliman P, Izpisua Belmonte JC, Chien K, Ruiz-Lozano P. (2005) Epicardial Retinoid X receptor alpha is required for myocardial growth and coronary artery formation. **Proc Natl Acad Sci USA,** 102:18455-60. PMID: 16352730

98. Kawakami Y*, **Raya A***, Raya RM, Rodriguez-Esteban C, Izpisua Belmonte JC. (2005) Retinoic acid signaling links left-right asymmetric patterning and bilaterally symmetric somitogenesis in the zebrafish embryo. **Nature,** 435:165-71. PMID: 15889082
99. Matsui T, **Raya A**, Kawakami Y, Callol C, Capdevila J, Rodriguez-Esteban C, Izpisua Belmonte JC. (2005) Non-canonical Wnt signaling regulates midline convergence of organ primordia during zebrafish development. **Genes Dev,** 19:164-75. PMID: 15630025

2004

100. **Raya A**, Izpisúa Belmonte JC. (2004) Sequential transfer of left-right information during vertebrate embryo development. **Curr Op Gen Dev,** 14:575-81. PMID: 15380250
101. **Raya A**, Izpisua Belmonte JC. (2004) Unveiling the establishment of left-right asymmetry in the chick embryo. **Mech Dev,** 121:1043-54. PMID: 15296970
102. Huang Q, **Raya A**, DeJesus P, Chao SH, Quon KC, Caldwell JS, Chanda SK, Izpisua-Belmonte JC, Schultz PG. (2004) Identification of p53 regulators by genome-wide functional analysis. **Proc Natl Acad Sci USA,** 101:3456-61. PMID: 14990790
103. **Raya A**, Kawakami Y, Rodriguez-Esteban C, Ibañes M, Rasskin-Gutman D, Rodriguez-León J, Büscher D, Feijó JA, Izpisúa Belmonte JC. (2004) Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination. **Nature,** 427:121-8. PMID: 14712268
104. **Raya A**, Consiglio A, Kawakami Y, Rodriguez-Esteban C, Izpisúa-Belmonte JC. (2004) The zebrafish as a model of heart regeneration. **Cloning Stem Cells,** 6:345-51. PMID: 15671662
105. Timmerman LA, Grego-Bessa J, **Raya A**, Bertrán E, Pérez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisúa Belmonte JC, de la Pompa JL. (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. **Genes Dev,** 18:99-115. PMID: 14701881

2003

106. **Raya A**, Koth CM, Büscher D, Kawakami Y, Itoh T, Raya RM, Sternik G, Tsai HJ, Rodriguez-Esteban C, Izpisúa Belmonte JC. (2003) Activation of Notch signaling pathway precedes heart regeneration in zebrafish. **Proc Natl Acad Sci USA,** 100(Suppl 1):11889-95. PMID: 12909711
107. Kawakami Y, Rodriguez-Leon J, Koth CM, Büscher D, Itoh T, **Raya A**, Ng JK, Rodriguez Esteban C, Takahashi S, Henrique D, Schwarz MF, Asahara H, Izpisúa Belmonte JC. (2003) MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. **Nat Cell Biol,** 5:513-9. PMID: 12766772
108. **Raya A**, Kawakami Y, Rodriguez-Esteban C, Büscher D, Koth CM, Itoh T, Morita M, Raya RM, Dubova I, Grego Bessa J, de la Pompa JL, Izpisúa Belmonte JC. (2003) Notch activity induces Nodal expression and mediates the establishment of left-right asymmetry in vertebrate embryos. **Genes Dev,** 17:1213-8. PMID: 12730123

2002

109. Ng J*, Kawakami Y*, Büscher D*, **Raya A***, Itoh T, Koth C, Rodríguez Esteban C, Rodriguez Leon J, Garrity DM, Fishman MC, Izpisúa Belmonte JC. (2002) The limb identity gene Tbx5 promotes limb initiation by interacting with Wnt-2b and Fgf-10. **Development,** 129:5161-70. PMID: 12399308

2001

110. Rodriguez-Esteban C, **Raya A**, Capdevila J, Izpisúa Belmonte JC. (2001) Cómo distingue el cuerpo la izquierda de la derecha? **Investigación y Ciencia,** 300:62-69.

2000

111. **Raya A**, Revert-Ros F, Martinez-Martinez P, Navarro S, Roselló E, Vieites B, Granero F, Forteza J, Saus J. (2000) Goodpasture antigen-binding protein, the kinase that phosphorylates the Goodpasture antigen, is an alternative spliced variant implicated in autoimmune pathogenesis. **J Biol Chem,** 275:40392-9. PMID: 11007769

1999

112. **Raya A**, Revert F, Navarro S, Saus J. (1999) Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen. **J Biol Chem,** 274:12642-9. PMID: 10212244

1990-1995

113. **Raya A**, Gallego J, Bosch-Morell F, Romá J, Romero FJ. (1995) Phenytoin-induced glutathione depletion in rat peripheral nerve. **Free Radic Biol Med,** 19:665-7. PMID: 8529926
114. Nagamatsu M, Nickander K, Schmelzer JD, **Raya A**, Wittrock DA, Tritschler H, Low PA. (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction velocity in experimental diabetic neuropathy. **Diabetes Care,** 18:1160-7. PMID: 7587852
115. Martínez MC, Bosch-Morell F, **Raya A**, Romá J, Aldasoro M, Vila J, Lluch S, Romero FJ. (1994) 4-Hydroxynonenal, a lipid peroxidation product, induces relaxation of human cerebral arteries. **J Cerebr Blood Flow Metab,** 14:693-6. PMID: 8014218
116. Higueras V, **Raya A**, Rodrigo JM, Serra MA, Romá J, Romero FJ. (1994) Interferon decreases serum lipid peroxidation products of hepatitis C patients. **Free Radic Biol Med,** 16:131-3. PMID: 7507878
117. Bosch-Morell F, Díaz-Llopis M, **Raya A**, Hermenegildo C, Puertas FJ, Romá J, Romero FJ. (1994) Novel aspects of antioxidants and lipid peroxidation in ophthalmic disease. **Life Chem Rep,** 12:101-104.
118. **Raya A**, Cuervo AM, Macián F, Romero FJ, Romá J. (1994) Nerve conduction velocity decrease and synaptic transmission alterations in caffeine-treated rats. **Neurotoxicol Teratol,** 16:11-5. PMID: 8183184
119. Hermenegildo C, **Raya A**, Romá J, Romero FJ. (1993) Decreased glutathione peroxidase activity in sciatic nerve of alloxan- induced diabetic mice and its correlation with blood glucose levels. **Neurochem Res,** 18:893-6. PMID: 8396737
120. **Raya A**, Romá J, Hermenegildo C, Romero FJ. (1993) Alterations in the antioxidant defense of peripheral nervous tissue following acute ethanol administration. **Biochem Soc Trans,** 21:92S. PMID: 8359545
121. Puertas FJ, Díaz-Llopis M, Chipont E, Romá J, **Raya A**, Romero FJ. (1993) Glutathione system of human retina: enzymatic conjugation of lipid peroxidation products. **Free Radic Biol Med,** 14:549-51. PMID: 8349144
122. **Raya A**, Gallego J, Hermenegildo C, Puertas FJ, Romero FJ, Felipo V, Miñana MD, Grisolía S, Romá J. (1992) Prevention of the acute neurotoxic effects of phenytoin on rat peripheral nerve by H7, an inhibitor of protein kinase C. **Toxicology,** 75:249-56. PMID: 1333652
123. Romá J, Cuervo AM, Macian F, **Raya A**, Gallego J, Llopis JE, Romero FJ. (1990) Temperature dependence of the toxic effects of phenytoin on peripheral neuromuscular function of the rat tail. **Neurotoxicol Teratol,** 12:627-31. PMID: 2255306

Research Grants:

1. **Title:** Investigación industrial para la obtención de nuevas fuentes proteicas alternativas, sostenibles, nutritivas y trazables a través de bioprocesos mediante uso de IA. **Project Coordinator:** Grupo Jorge SL; **Principal Investigator:** Angel Raya. **Agency:** Spanish Ministry for Science and Innovation; **Type:** Programa de Misiones de Ciencia e Innovación - MIG-20221025; **Duration:** 2022-2024; Total Amount: 2.874.341 €; Budget for A. Raya: 505.925 €
2. **Title:** Investigating the microenvironment adaptations that control cardiac regeneration/repair (Micro-RegHeart). **Principal Investigator:** Angel Raya. **Agency:** Spanish Ministry for Science and Innovation; **Type:** PID2021-123925OB-I00; **Duration:** 2022-2025; Total Amount: 311.938 €
3. **Title:** Pseudohypoxia-mediated cardiac regeneration. Researcher: Daniel Uribe. **Principal Investigator:** Angel Raya **Agency**: European Commission; **Type:** H2020-MSCA-IF-2020-101027429. **Duration**: 2022-2023; Total Amount: 160.932 €
4. **Title:** Polymeric cell-laden vascular graft for blood vessel mimicking in tissue engineering applications. Researcher: Jagoda Litowczenko. **Principal Investigator:** Angel Raya **Agency**: European Commission; **Type:** H2020-MSCA-IF-2020 **Duration**: 2022-2023; Total Amount: 160.932€
5. **Title:** Investigating the mechanistic links between extracellular matrix properties and heart regeneration/repair (ECM-RegHeart). **Principal Investigator:** Angel Raya. **Agency:** Spanish Ministry for Science, Innovation and Universities; **Type:** RTI2018-095377-B-100; **Duration:** 2019-2021; Total Amount: 302.500 €
6. **Title:** Allogeneic iPSC from cord blood units homozygous for highly prevalent haplotypes (iPS-PANIA). **Principal Investigator:** Angel Raya/Anna Veiga. **Project Coordinator:** Sergi Querol (BST).

Agency: MICINN; **Type:** RETOS (RTC-2017-6000-1); **Duration:** 2018-2020; Total amount: 603,721 €; Amount granted to A. Raya: 122,060 €

7. **Title:** Networking Center of Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) **Principal Investigator**: Angel Raya **Agency:** Spanish Health Ministry "Instituto de Salud Carlos III" (CB06/01/1056); **Duration:** 2016-2020; Amount granted to A. Raya: 310,157 €
8. **Title:** Red de Terapia Celular (TerCel). **Principal Investigator:** Angel Raya. **Agency:** Instituto de Salud Carlos III (RD16/0011/0024); **Duration:** 2017-2021; Amount granted to A. Raya: 240,245 €
9. **Title:** Cardiopoesi amb biomatrius per regenerar la cicatriu post infart: From bench to bedside (first-in-man trial). **Principal Investigator:** Angel Raya. **Project Coordinator**: Antoni Bayès-Genís (IGTP). **Agency:** Departament de Salut, Generalitat de Catalunya; **Type:** PERIS SLT002/16/00234; **Duration:** 2017-2019; Total amount: 738,695 €; Amount granted to A. Raya: 218,088 €
10. **Title:** Biomedical applications of iPS cell technology. **Principal Investigator:** Angel Raya. **Agency:** AGAUR; **Type:** 2017 SGR 899; **Duration:** 2017-2019; Total amount: 42,000 €
11. **Title:** Design of strategies for controlling the proliferation, differentiation, and maturation of human cardiomyocytes. **Principal Investigator:** Angel Raya. **Agency:** Spanish Ministry for Economy and Competitiveness; **Type:** SAF2015-69706-R; **Duration:** 2016-2018; Total amount: 278,300 €
12. **Title:** Investigating genetic and mechanistic interactors in familial cardiomyopathy through advanced disease modeling. **Project Coordinator:** Angel Raya **Agency:** Fundació La Marató de TV3**", Type:** Research Projects on Heart Disease; **Duration:** 2016-2018; Total amount: 399,875 €; Amount granted to A. Raya: 149,875 €
13. **Title:** Molecular links between diabetes and neurodegenerative disorders. **Project Coordinator:** Angel Raya **Agency:** Spanish Health Ministry "Instituto de Salud Carlos III", **Type:** Integrated Projects of Excellence PIE14/00061; **Duration:** 2015-2017; Total amount: 660,000 €; Amount granted to A. Raya: 50,000 €
14. **Title:** Biomedical applications of iPS cell technology. **Principal Investigator:** Angel Raya **Agency:** AGAUR; **Type**: 2014 SGR 1460; **Duration:** 2015-2016; Total amount: 40,000 €
15. **Title:** Perpetuating NF1+/- and NF1-/- plexiform neurofibroma-derived tumor cells through the generation of induced pluripotent stem (iPS) cells. **Principal Investigator:** Angel Raya. **Project Coordinator:** Eduard Serra (IMPPC, Barcelona) **Agency:** NTAP at Johns Hopkins; **Duration:** 2013-2014; Amount granted to A. Raya: $82,500
16. **Title:** Estudio de la replicación "tipo prión" en modelos celulares obtenidos mediante la reprogramación de células somáticas de pacientes genéticamente susceptibles a la enfermedad de Alzheimer. **Principal Investigator:** Angel Raya. **Project Coordinator:** Joaquín Castilla (CIC bioGUNE, Derio) **Agency:** BIOEF; **Type**: BIO12/AL/004; **Duration:** 2013-2014; Amount granted to A. Raya: 28,080 €
17. **Title:** Bioengineering approach to cardiac regeneration/repair. **Principal Investigator:** Angel Raya **Agency:** Spanish Ministry for Economy and Competitiveness; **Type:** SAF2012-33526; **Duration:** 2013-2015; Total amount: 278,300 €
18. **Title:** Use of patient-specific induced pluripotent stem cells to improve diagnosis and treatment of hemophilia A (HEMO-iPS) **Principal Investigator:** Angel Raya. **Project Coordinator:** Jordi Barquinero (Vall d'Hebron, Barcelona) **Agency:** Spanish Health Ministry "Instituto de Salud Carlos III", under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases, **Type:** E-Rare JCT 2011; **Duration:** 2012-2014; Amount granted to A. Raya: 75,000 €
19. **Title:** Generation of a dopaminergic neuron model based on induced pluripotent stem cells from patients suffering Parkinson's disease associated with LRRK2 mutations. **Principal Investigator:** Angel Raya. **Project Coordinator:** Eduard Tolosa (Hospital Clínic, Barcelona) **Agency:** Spanish Health Ministry "Instituto de Salud Carlos III"; **Type:** CIBERNED Collaborative Projects PI2010/05; **Duration:** 2011-2013; Amount granted to A. Raya: 52,500 €
20. **Title:** Networking Center of Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) **Principal Investigator**: Angel Raya **Agency:** Spanish Health Ministry "Instituto de Salud Carlos III" (CB06/01/1056); **Duration:** 2008-2015; Amount granted to A. Raya: 249,450 €

21. **Title:** Reparación de Cartílago Articular mediante Ingeniería de Tejidos in situ: modelo in vivo (iPSC). **Principal Investigator:** Angel Raya **Agency:** MICINN (ACI-2010-1117); **Duration:** 2009-2012. Amount granted to A. Raya: 64,917 €
22. **Title:** Human pluripotent stem cells and zebrafish heart regeneration as experimental tools to understand cardiac muscle cell differentiation. **Principal Investigator:** Angel Raya **Agency:** MICINN (BFU2009-13277); **Duration:** 2010-2012. Amount granted to A. Raya: 266,200 €.
23. **Title:** In situ tissue engineering using stem cells and functional biomaterials to repair articular cartilage: An "in vivo model". **Principal Investigator:** Angel Raya **Project Coordinator:** F. Blanco (INIBIC-CH Universitario A Coruña) **Agency:** MICINN (ACI-PLE2009-0144); **Duration:** 2009-2012; Amount granted to A. Raya: 179,297 €
24. **Title:** Developing high-throughput bioassays for human cancers in zebrafish (ZF-CANCER). **Principal Investigator:** Juan Carlos Izpisúa **Agency:** Comisión Europea (FP7-GA-201439) 280,000 € **Duration:** 2008-2011.
25. **Title:** Molecular and cellular bases of heart regeneration in the zebrafish (RegenZebra). **Principal Investigator:** Angel Raya **Agency:** Comisión Europea. Marie Curie IRG (FP6-046523); **Duration:** 2007-2010. Amount granted to A. Raya: 80,000 €
26. **Title:** Red de Terapia Celular (TerCel). **Principal Investigator:** Juan Carlos Izpisúa, Angel Raya, Anna Veiga **Agency:** Instituto de Salud Carlos III (RD06/0010/0016) 190,000 €/year) **Duration:** 2006-2010.
27. **Title:** Cellular and molecular bases and functional implications of adult hippocampal neurogenesis; implications for the pathogenesis Alzheimer's disease. **Principal Investigator:** Juan Carlos Izpisúa **Agency:** Fundación La Marató de TV3 (63430) **Duration:** 2007-2010.
28. **Title:** Bases moleculares y celulares de la regeneración cardiaca en el pez cebra. **Principal Investigator:** Angel Raya **Agency:** Ministerio de Educación y Ciencia (BFU2006-12251/BMC) **Duration:** 2006-2009; Amount granted to A. Raya: 254,100 €
29. **Title:** Notch Signaling and Left-Right Asymmetry Determination. **Principal Investigator:** Juan Carlos Izpisúa **Agency:** National Institutes of Health (2R01HD034538-06A1) **Duration:** 2003-2008.
30. **Title:** Interaction of BMP, WNT and SHH in the Vertebrate Limb. **Principal Investigator:** Juan Carlos Izpisúa **Agency:** National Institutes of Health (5R01HD042167-04) **Duration:** 2002-2006.
31. **Title:** Notch signaling and vertebrate limb development. **Principal Investigator:** Juan Carlos Izpisúa **Agency:** National Institutes of Health (1R01HD034538-01A2) **Duration:** 1997-2002.
32. **Title:** Molecular mechanism of drug-induced autoimmune hepatitis. **Principal Investigator:** Juan Saus Mas **Agency:** Generalitat Valenciana (GV-C-VS-21-118-96) **Duration:** 1997-1999.
33. **Title:** Characterization of elements and transcription factors that regulate negatively the expression of human stromelysin-1 and –2. **Principal Investigator:** Juan Saus Mas **Agency:** CICYT (PM95/0051) **Duration:** 1996-1999.
34. **Title:** Role of antioxidants in the molecular mechanisms of toxicity. Ethanol and peripheral nervous system: metabolic, electrophysiological and ultrastructural correlations. **Principal Investigator:** Francisco Javier Romero Gómez **Agency:** DGICYT (PM92/0146) **Duration:** 1992-1995.

Research Contracts:

1. **Title:** Caracterización detallada de la capacidad de lotes industriales regulatorios del producto para promover la generación de células madre humanas con pluripotencia inducida **Principal Investigator:** Angel Raya **Company:** Instituto Grifols **Duration:** 04/2011-03/2012.
2. **Title:** Estudios de estabilidad sobre materiales de industrialización del producto para mantener el estado indiferenciado de células madre humanas con pluripotencia inducida **Principal Investigator:** Angel Raya **Company:** Instituto Grifols **Duration:** 04/2011-10/2011.
3. **Title:** Preliminary test of zebrafish larvae for cardiotoxicity assays (TOXFDS-006-11) **Principal Investigator:** Angel Raya **Company:** Ferrer Group Internacional **Duration:** 03/2011-06/2011.

Patents:

1. Inventors: Raya, A., Aasen, T, Belmonte, JC
   Title: Induced pluripotent stem cells and methods of use.

Organism: Centre de Medicina Regenerativa de Barcelona
Application number: 61/100,110 - Patent priority country: USA - Patent priority date: 25/09/2008

2. Inventors: Kawamura, T., Suzuki, J., Wang, Y.V., Raya, A., Wahl, G.M., Izpisúa Belmonte, J.C.
Title: Induced pluripotent stem cell generation using two factors and p53 inactivation.
Organism: Salk Institute for Biological Studies
Application number: 61/163,386 - Patent priority country: USA - Patent priority date: 25/03/2009

3. Inventors: Raya, A., Bueren, J., Izpisúa Belmonte, J.C.
Title: Generation of genetically corrected disease-free induced pluripotent stem cells.
Organisms: CMRB/Salk Institute for Biological Studies/CIEMAT
Application number: 61/181,287 - Patent priority country: USA - Patent priority date: 27/05/2009

4. Inventors: Valls-Margarit M, Iglesias O, Jane R, Martinez E, Raya A
Title: Human cardiac tissue construct, related methods of use.
Organisms: CMRB/IBEC
Application number: EP18382391 - Patent priority country: EU - Patent priority date: 04/06/2018

Mentoring PhD & MSc Theses:

2022 PhD Thesis Director “Investigating genetic and mechanistic interactors in familial cardiomyopathy through advanced disease modeling”, by Ruben Escriba Piera, Universitat de Barcelona, 17/03/2022; Excellent ‘cum laude’

2021 Curriculum Practical Term Supervisor of Marc Ibañez, Major in Biotechnology, Universitat de Vic

2021 TFG Supervisor “Role of ECM mechanical properties in cell-autonomous behaviors of zebrafish cardiomyocytes” by Vassilliki Tassou, Major in Biological Applications and Technology, University of Ioannina

2019 MSc Thesis Director “Hypertrophic cardiomyopathy *in vitro* biomimetic model using human induced pluripotent stem cells”, by Eunyeong Kim, Universitat de Barcelona

2019 PhD Thesis Director “Study of extracellular matrix remodeling and the role of periostin b during zebrafish heart regeneration”, by Anna Garcia-Puig, Universitat de Barcelona, 22/03/2019; Excellent ‘cum laude’

2018 TGF Supervisor “Generation and validation of experimental models of human cardiac disease based on patient-specific iPS cells”, by Ipek Yaren Aktan, Major in Genetic and Bioengineering, Istanbul Bilgi University

2018 MSc Thesis Director “CRISPR/Cas9-based genome edition in zebrafish”, by Elisa Hahn, University of Applied Sciences Technikum Wien

2017 PhD Thesis Co-Director “Investigating the genetic componen of Parkinson’s disease through the use of human induced plutipotent stem cells and gene editing”, by Carles Calatayud Aristoy, Universitat de Barcelona, 14/09/2017; Excellent ‘cum laude’

2017 PhD Thesis Co-Director “Development of an advanced 3D culture system for human cardiac tissue engineering”, by Maria Valls Margarit, Universitat de Barcelona, 07/07/2017; Excellent ‘cum laude’

2016 MSc Thesis “Cardiac tissue engineering with human iPS-derived cardiomyocytes”, by Leonard Gable, École Polytechnique Fédérale de Lausanne

2016 TFG Supervisor “Implementation of a straightforward three-dimensional culture method in suspension for scalable expansion and differentiation of human induced pluripotent stem cells”, by Alessia Urzì, Major in Medical Biotechnologies, Università degli Studi di Padova

2016 PhD Thesis Director "Development of a biomimetic mechanical stimulation system to improve the maturation of human iPS-derived myocardial grafts”, by Juan Crespo Santiago, Universitat de Barcelona, 21/07/2016; Excellent ‘cum laude’

2016 PhD Thesis Director "Biotechnological approaches to cardiac differentiation of human induced pluripotent stem cells", by Claudia Di Guglielmo, Universitat de Barcelona, 09/02/2016; Excellent ‘cum laude’

2016 PhD Thesis Director "Bioengineering approach to study the role of cell migration during zebrafish heart regeneration", by Isil Tekeli, Universitat de Barcelona, 03/02/2016; Excellent 'cum laude'
2015 MSc Thesis Director "Assessing actin-cMyBP-C interactions in iPS cell-derived cardiomyocytes", by Jonathan De Smedt, Transnationale Universiteit Limburg
2014 TFG Supervisor "Molecular characterizarion of the reprogramming status on human induced pluripotent stem cell lines", by Qi Zhu, Major in Biology, Universitat de Barcelona
2014 MSc Thesis Director "Gene expression analysis of fhl3a and epicardial cell migration during heart regeneration in zebrafish", by Kervy Carola Fernandez, Université Pierre et Marie Curie Paris VI
2014 MSc Thesis Director "Improvement of a human-plasma derived animal-free cell culture supplement (SCC) for the culture of Induced Pluripotent Stem Cells (iPSC)", by Arnau Biosca, Universitat de Barcelona
2013 MSc Thesis Director "Development of a decellularization protocol to study the role of extracellular matrix proteins during zebrafish heart regeneration", by Isabel Maria Silva Teixeira Ramos, Universidade do Porto
2013 MSc Thesis Director "Generación y caracterización de líneas celulares de células madre pluripotentes inducidas obtenidas de pacientes con hemofilia", by Juan Luis Vázquez Rentería, Universitat de Barcelona
2013 MSc Thesis Director "Investigating Epigenetic Memory in Induced Pluripotent Stem Cells", by Dalel Saidi, Universitat de Barcelona
2013 MSc Thesis Director "Characterization of transgenic human induced pluripotent stem cell line reporter for cardiac differentiation using forced aggregation devices", by Laia Gregori Gonzalo, Universitat Autònoma de Barcelona
2012 PhD Thesis Co-Director "Generation of human dopaminergic neurons from induced pluripotent stem cells to model Parkinson's disease", by Adriana Sánchez-Danés, Universitat Pompeu Fabra, 21/05/2012; Excellent 'cum laude'
2011 MSc Thesis Director "Bioengineering approach to study zebrafish heart function and regeneration", by Isil Tekeli, Universitat de Barcelona
2011 MSc Thesis Director "Using transgenic human embryonic stem cells for the study of Notch signaling pathway in the control of potency and differentiation of stem cells", by Bahaa Arefai, Universitat de Barcelona
2010 MSc Thesis Director "Dediferenciación de cardiomiocitos en pez cebra", by Marta Lorente Anés, Universitat de Barcelona
2010 PhD Thesis Co-Director "Development of xenobiotic-free conditions towards the generation and propagation of clinically-safe human pluripotent cells", by Ignasi Rodríguez Pizà, Universitat Pompeu Fabra, 05/07/2010; Excellent 'cum laude'
2010 PhD Thesis Director "Molecular and cellular bases of heart regeneration in zebrafish", by Eduard Sleep Ronquillo, Universitat Pompeu Fabra, 30/06/2010; Excellent 'cum laude'
2009 MSc Thesis Director "Heart Regeneration in Zebrafish", by Clara Fernández Pons, Universitat de Barcelona

Invited talks to Conferences and Meetings:

- Intrinsic and extrinsic determinants of embryonic stem cell pluripotency. European Spring School in Regenerative Medicine. Oslo, Norway. Invited speaker; May 2007
- Regulation of pluripotency in embryonic stem cells. EPFL Seminar Series. Lausanne, Switzerland. Invited talk; September 2007
- Brainstorming on Regenerative Medicine Research. European Commission Expert Meeting. Brussels, Belgium. Invited participation; September 2007
- Mechanisms of pluripotency in hESC. 1st European Human Embryonic Stem Cell registry (hESCreg) Symposium. Berlin, Germany. Invited speaker; January 2008
- Establishment and maintenance of pluripotency in stem cells. Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam. Invited talk; February 2008
- Generation of patient-specific iPS cells. Keystone Symposium: Signaling Pathways in Cancer and Development. Steamboat Springs, Colorado. Invited speaker; March 2008

- Stem Cells and Regenerative Medicine. 8th International Symposium on Preimplantation Genetic Diagnosis. Barcelona. Invited speaker; April 2008
- Establishment and maintenance of stem cells pluripotency. Institut de Recerca Hospital Universitari Vall d'Hebron - Seminar Series. Barcelona. Invited talk. May 2008
- Generation of patient-specific iPS cells. BioMed Seminar - Institut de Recerca Biomèdica, Parc Científic de Barcelona. Barcelona. Invited talk; July 2008
- Towards personalized reprogramming strategies for regenerative medicine. IMPPC Miniworkshop. Badalona, Spain. Invited talk; December 2008
- Reprogramming of human somatic cells to pluripotency with defined factors. ESHRE Stem Cells Expert Meeting. Lugano, Switzerland. Invited participation; March 2009
- Reprogramming somatic cells for modeling and treating human disease. MRC Induced Pluripotent Stem Cells Workshop. London, UK. Keynote Speaker; April 2009
- Reprogramming somatic cells for the generation of human patient-specific iPS cells. CNIC Seminar Series. Madrid, Spain. Invited talk; April 2009
- New developments in the generation of patient specific induced pluripotent cells. 25th ESHRE Annual Meeting. Amsterdam, The Netherlands. Invited speaker; June 2009
- Generación de cardiomiocitos a partir de células embrionarias. V Congreso de la Sociedad Española de Terapia Génica y Celular. Granada. Plenary session; October 2009.
- Mecanismos genéticos y epigenéticos determinantes de la respuesta regeneradora en vertebrados: el papel de las células madre. Perspectivas en la investigación con células troncales: Aspectos científicos, éticos, sociales y legales. Granada. Invited speaker; October 2009.
- Utilización de células madre con pluripotencia inducida (iPS) para modelar y tratar enfermedades humanas. Ciclo de Seminarios de Investigación del IBIS/Hospital Universitario Virgen del Rocío. Sevilla. Invited speaker; November 2009.
- Generation of disease-free hematopoietic progenitors from dermal fibroblasts and keratinocytes from Fanconi anemia patients. V Simposium Nacional sobre Anemia de Fanconi. Barcelona. Invited speaker; November 2009.
- Terapéutica de la enfermedad genética. 4º Curso de Genética Humana de la Sociedad Española de Genética. Barcelona. Invited speaker; February 2010.
- Cell reprogramming (induced pluripotent stem cells, iPS). ESHRE Basic Course on “Update on pluripotent stem cells (hESC AND iPS)”. Barcelona. Invited speaker; February 2010.
- Using induced pluripotent stem cells to treat and model human disease. ESTOOLS International Symposium: Stem Cells in Biology and Disease. Lisbon. Invited speaker; May 2010.
- Modeling and treating human genetic disease with induced pluripotent stem (iPS) cells. European Human Genetics Conference 2010. Gothenburg. Invited speaker; June 2010.
- Using iPS cell technology to model and treat human disease. Bone Marrow Transplantation Seminar Series, University of Minnesota. Minneapolis. Invited speaker; June 2010.
- Modeling human disease through patient-specific iPS cells. Jornada Red TerCel “Reprogramación celular y células madre con pluripotencia inducida (células iPS). Madrid. Co-organizer, session chairman, invited speaker; July 2010.
- New opportunities for modeling human disease through iPS cell technology. Inbiomed Seminar Series, San Sebastian. Invited speaker; September 2010.
- Modeling human disease through iPS cell technology. IDIBELL Seminar Series, Barcelona. Invited speaker; October 2010.
- Cell reprogramming (induced pluripotent stem cells, iPS). ESHRE Basic Course on “Update on pluripotent stem cells (hESC AND iPS)”. Valencia. Invited speaker; November 2010.
- On the cellular bases of zebrafish heart regeneration. IBUB Symposium “From Stem Cells to Regeneration: Models in Tissue Regeneration”. Barcelona. Invited speaker; November 2010.
- Treating and modeling human disease through induced pluripotent stem (iPS) cell technology. OncoBio 2010: Cancer, Stem Cells, and Metastasis. Salamanca. Invited speaker; November 2010.
- Novos Avances en Células Nai con Pluripotencia Inducida. Hospital Clínico Universitario de Santiago Seminar Series. Santiago de Compostela. Invited speaker; January 2011.

- Reprogramming the potency of somatic cells: how and what for? IBEC Seminar Series. Barcelona. Invited speaker; March 2011.
- Prospects for modeling and treating human disease through induced pluripotent stem cells. Dipartimento di Scienze Biomediche e Biotecnologie Seminar Series. Brescia, Italy. Invited speaker; April 2011.
- Células madre con pluripotencia inducida (iPS). CemCat Postgraduate Course on “Neuroinmunología - Seminarios de Formación Continuada”. Barcelona. Invited speaker; May 2011.
- iPS cells as a model system to study cancer and regeneration. Advanced Summer School “Interrogations at the Biointerface: The cancer/regeneration interface”. Porto, Portugal. Co-organizer, session chairman, invited speaker; June 2011.
- Investigación con células madre pluripotentes humanas: oportunidades y limitaciones. Institut d’Estudis de la Salut Postgraduate Course on Bioethics. Barcelona. Closing address; June 2011.
- Células madre pluripotentes inducidas: posibles aplicaciones clínicas. Course on “Trasplante hematopoyético y terapia celular: medicina reparadora” from Universidad Internacional del Mar. Aguilas. Invited speaker; July 2011.
- How do zebrafish regenerate their hearts? VI Congreso de la Sociedad Española de Terapia Génica y Celular, Zaragoza. Invited speaker, September 2011.
- What we learned from reprogramming FA somatic cells to pluripotency. 23rd Annual Fanconi Anemia Research Fund Scientific Symposium. Barcelona. Invited speaker, October 2011.
- Bases cel·lulars de la regeneració miocàrdica en el peix zebra. Jornada OCATT “Avenços en recerca i tractament de patologia cardíaca i vascular. Barcelona. Invited speaker, October 2011.
- Modeling age-related neurodegeneration in vitro with iPS cells. Myoage Workshop “Inflammation and ECM remodeling in ageing”. Barcelona. Invited speaker, December 2011.
- Modeling Parkinson's disease with induced pluripotent stem cells. XIV Congreso de la Sociedad Española de Biología Celular. Torremolinos. Keynote speaker, December 2011.
- Reprogramación de células humanas a células madre pluripotentes. XXIII Congreso Nacional de la Sociedad Española de Diabetes. Vigo. Plenary address; April 2012.
- 2012 OARSI World Congress. Barcelona. Chair of Concurrent Session 14: Regenerative Medicine in OA; April 2012.
- Advanced Summer School “Interrogations at the Biointerface: The self-renewal/differentiation interface”, Barcelona. Co-organizer, session chairman; June 2012.
- Reprogramming the potency of somatic cells: How and what for? Societat Catalana de Biologia 1912-2012. Global Questions on Advanced Biology. Barcelona. Invited speaker; July 2012.
- Aplicaciones de las células madre con pluripotencia inducida (iPS) en investigación biomédica. VI XORNADA CIENTÍFICA: Terapia Celular e Medicina Rexenerativa. A Coruña. Invited speaker; October 2012.
- Biomedical applications of induced pluripotent stem (iPS) cells. Seminar Series Università del Piemonte Orientale "A.Avogadro". Novara, Italy. Invited speaker; November 2012.
- Models de malalties humanes mijantçant cél.lules iPS. SESSIONS CIENTÍFIQUES 2012, INSTITUT DEL TÓRAX-SERVEI DE PNEUMOLOGIA, Hospital Clínic, Barcelona. Invited speaker; November 2012.
- Premi Nobel de Fisiologia o Medicina 2012: Reprogramant el destí de les cèl·lules. 14th Conferences cycle of the Institut d’Estudis Catalans, Barcelona. Invited speaker; December 2012.
- Premi Nobel de Fisiologia o Medicina 2012: Reprogramant el destí de les cèl·lules. 14th Conferences cycle of the Institut d’Estudis Catalans, Valencia. Invited speaker; January 2013.
- Control of stem cell potency. IBEC-IBMB workshop: Cells in motion, Barcelona. Invited speaker; February 2013.
- Aplicaciones biomédicas de las células madre con pluripotencia inducida (iPS). XVIII Jornada de Diabetes en el Niño y Adolescente de la SEEP, Madrid. Invited speaker; March 2013.
- Induced pluripotent stem (iPS) cells. Seminar series of Instituto de Biologia y Genetica Molecular (IBGM), Valladolid. Invited speaker; May 2013.
- Reprogramación y sus aplicaciones para el estudio de la enfermedad de Parkinson. XLV Lección Conmemorativa Jiménez Díaz, Madrid. Invited speaker; May 2013.

- Advanced Summer School “Interrogations at the Biointerface: The inflammation/repair interface”. Porto, Portugal. Co-organizer, session chairman; June 2013.
- iPSC as a therapeutic tool. International Summer Course “Cell therapy from the bench to the bedside and return” from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2013.
- Modelización de enfermedades humanas mediante células iPS: posibilidades y limitaciones. XXXVI Congreso de la SEBBM, Madrid. Invited speaker; September 2013.
- Modeling human disease through iPS cell technology. University of Bari, Department of Basic Medical Sciences Seminar series, Bari. Invited speaker; September 2013.
- iPS cells in biology and disease. IDMC-9 International Myotonic Dystrophy Consortium Meeting, San Sebastián. Keynote speaker; September 2013.
- Modeling neurodegenerative disease through iPS cell technology. ESGCT and SETGyC Collaborative Congress, Madrid. Session chair and Invited speaker; October 2013.
- Using iPS cell technology to model human neurodegenerative diseases. Life Technologies’ “24 hours of stem cells” virtual meeting. Invited participant; November 2013.
- Biomedical applications of induced pluripotent stem (iPS) cells. CBMSO Seminar Series, Madrid. Invited speaker; December 2013.
- Fronteres de la manipulació genètica humana. Cicle de conferències “Ciència al Nadal” de l’Institut de Biología Evolutiva (UPF-CSIC), PRBB, Barcelona. Invited speaker; December 2013.
- Leveraging iPS cell technology for biomedical research. Seminar Instituto Cajal, Madrid. Invited speaker; February 2014.
- Conferència Santiago Ramon i Cajal: Cèl·lules mare pluripotencials induïdes (iPS) en neurología. XVIII Reunió Anual de la Societat Catalana de Neurología, Sitges. Invited speaker; March 2014.
- Què són les cel·lules mare? Café Cientific (CRG), Barcelona. Invited speaker; April 2014.
- The disruptive power of cellular reprogramming to treat human disease. MIHealth Forum, Barcelona. Keynote speaker; May 2014.
- What's new in stem cell therapy for cardiac repair? 11th International Symposium on Stem Cell Therapy & Cardiovascular Innovations, Madrid. Session chairman; May 2014.
- Leveraging IPs Cell Technology for Biomedical Research. BioMed Plenary Seminar, Barcelona. Invited speaker; May 2014.
- Advanced Summer School “Interrogations at the Biointerface”, Barcelona. Co-organizer, session chairman; June 2014.
- iPS cells for human disease modeling. Frontiers in CardioVascular Biology, Barcelona. Invited speaker; July 2014.
- Reprogramación: nuevos modelos de enfermedad. Curso de verano de La Universidad Menéndez Pelayo: " Biotecnología y Salud: De la ciencia y tecnología al impacto socio-económico", Santander. Invited speaker; July 2014.
- iPSC as a Therapeutic Tool. “Cell therapy from the bench to the bedside and return” from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2014.
- Leveraging iPS cell technology for biomedical research. 16th European Neurofibromatosis Meeting, Barcelona. Keynote speaker; July 2014.
- Stem cells and regenerative processes. Workshop Integrated Cognition Institute (ICI): "Regenerative Medicine and Human Enhancement. A New Role of Old People in our Society?", Monestir de Poblet. Invited speaker; September 2014.
- Modeling Parkinson's disease through patient-specific induced pluripotent stem (iPS) cells. II Congreso Internacional de Investigación e Innovación en Enfermedades Neurodegenerativas (CIIIEN), Barcelona. Invited speaker; September 2014.
- ¿Se reparan los organismos? La revolución de las células madre. Open Day - Parc de Recerca Biomèdica Barcelona (PRBB), Barcelona. Invited speaker; October 2014.
- Células iPS en investigación biomédica: posibilidades y limitaciones. XLIV Congreso Nacional de la Sociedad Española de Nefrología, Barcelona. Keynote speaker; October 2014.
- Cèl·lules mare i medicina regenerativa: realitats i promeses. Cicle de conferències "Cèl·lules mare: un futur sense malalties?", Barcelona. Invited speaker; October 2014.

- Biomedical applications of iPS cell technology. 2nd International Annual Conference of the German Stem Cell Network (GSCN), Heidelberg, Germany. Invited speaker; October 2014.
- Modeling human neurodegenerative diseases using iPS cell technology. I Satellite Course CRG "Somatic Cell Reprogramming", Barcelona. Invited speaker; November 2014.
- Molecular links between Diabetes and Neurodegenerative Disorders. 8th CIBER-BBN Annual Conference, Barcelona. Invited speaker; November 2014.
- Modelaje de enfermedades genéticas y medicina regenerativa. 6º Curso de Genética Humana de la Sociedad Española de Genética, Barcelona. Invited speaker; November 2014.
- Using induced pluripotent stem (iPS) cell technology to model Parkinson's disease. Seminar - Achucarro Basque Center for Neuroscience, Zamudio. Invited speaker; December 2014.
- Biomedical applications of induced pluripotent stem (iPS) cells. Nature Publishing Group Conference, Madrid. Invited speaker; February 2015.
- Induced Pluripotent Stem (IPS) cells for Disease Modeling and Treatment. B-Debate: “Advanced Cellular Therapies and Regenerative Medicine – The promise in the 21st century”, Barcelona. Invited speaker; February 2015.
- Cèl·lules mare i medicina regenerativa. Col·legi de Biòlegs de Catalunya (CBC): "Actualització en Genètica Clínica”, Barcelona. Invited speaker; March 2015.
- Medicina regenerativa: reptes tècnics i fronteres ètiques. Instituto de Estudios Humanísticos Miquel Coll i Alentorn (INEHCA): “Retos sociales, científicos y tecnológicos para un futuro sostenible”, Terrassa. Invited speaker; March 2015.
- Biomedical applications of induced reprogramming. I Jornada Científica del Departament de Biologia Animal, Biologia Vegetal i Ecologia – UABio (Universitat Autònoma de Barcelona), Bellaterra. Invited speaker; June 2015.
- The many flavors of stem cells: stem cell types and their potential for regenerative medicine. Pre Congress Course Annual Meeting European Society of Human Reproduction and Embryology (ESHRE), Lisbon, Portugal. Invited speaker; June 2015.
- iPS cells for Cell Therapy – Science or Fiction. VIII Xornada Científica “Terapia Celular e Medicina Regenerativa” (Instituto de Investigación Biomédica de A Coruña), La Coruña. Invited speaker; June 2015.
- Advanced Summer School “Interrogations at the Biointerface: The inflammation/repair interface”. Porto, Portugal. Co-organizer; June 2015.
- iPSC as a Therapeutic Tool. “Cell therapy from the bench to the bedside and return” from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2015.
- Induced pluripotent stem cells: the new patient. European Society of Cardiology (ESC) Congress, London, United Kingdom. Invited speaker; August 2015.
- iPS-based approaches. B-Debate: “Future tools for biomedical research: In vitro, in silico and in vivo disease modeling”, Barcelona. Session chairman; October 2015.
- ¿Se reparan los organismos? La revolución de las células madre. Open Day - Parc de Recerca Biomèdica Barcelona (PRBB), Barcelona. Invited speaker; October 2015.
- Biomedical applications of induced reprogramming to pluripotency. Seminar – Universidad Carlos III, Madrid. Invited speaker; October 2015.
- Importancia de las células madre en medicina regenerativa. Fundació Oncovallès – Taula rodona: “Cèl·lules mare, Medicina Regenerativa i Càncer”, Granollers. Debate chairman; October 2015.
- Disease modelling using Ipsc. 8th Biennial Congress of the Spanish Society for Gene and Cell Therapy (SETGyC), San Sebastián. Co-organizer, Session chairman; November 2015.
- Nuevas estrategias en investigación. Papel de la medicina regenerativa. 11ª Jornada Anual de la “Asociación para la Información y la Investigación de las Enfermedades Renales Genéticas” (AIRG), Barcelona. Invited speaker; November 2015.
- Biomedical applications of induced reprogramming to pluripotency. II Congreso Biomedicina de Predocs de Valencia, Valencia. Invited speaker; November 2015.
- Modeling human neurodegenerative diseases through iPSC-based technology. 8th Guangzhou International Conference on Stem Cell and Regenerative Medicine, Guangzhou, China. Invited speaker; December 2015.

- Opportunities for modeling neurodegenerative diseases using iPS cell technology. Annual Congress of the SFTCG (Société Française de Thérapie Cellulaire et Génique), Marseille, France. Invited speaker; March 2016.
- Cossos amb recanvi"", Debate - Ateneu Barcelonès, Barcelona. Debate chairman; April 2016.
- Possibilities and limitations of iPSC-based human disease modeling. Ciclo de Conferencias Científicas – Congreso de Investigación Biomédica (CIB-2016) – Universitat de València, Valencia. Invited speaker; April 2016.
- Células iPS: de la investigación a la aplicación clínica. XXIVas Jornadas Mediterráneas de Confrontaciones Terapéuticas, Sitges. Keynote speaker; May 2016.
- Induced pluripotent stem cell-based studies: challenges and promises. European Society of Human Genetics (ESHG) Congress, Barcelona. Invited speaker; May 2016.
- Redefining cell identity through induced reprogramming. XXIII Jornades de Biologia Molecular (Societat Catalana de Biologia-SCB), Barcelona. Invited speaker; June 2016.
- iPSC as a therapeutic tool. International Summer Course "Cell therapy from the bench to the bedside and return" from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2016.
- La biotecnología en biomedicina. "Què és la biotecnología?" – Escola d'estiu de l'Escola Europea d'Humanitats, Barcelona. Invited speaker; July 2016.
- Opportunities of iPS Cell Technology for Modeling Neurodegenerative Diseases. iForum meeting (Cellular Dynamics International) at the Brain and Spine Institute in Paris, France. Invited speaker; October 2016.
- iPSC-based modeling of Parkinson's disease. "Changing the Face of Modern Medicine: Stem Cells and Gene Therapy" Joint European Society for Gene and Cell Therapy (ESGCT), International Society for Stem Cell Research (ISSCR) and Italian Association of Biologists working on Cells and Differentiation (ABCD), Florence, Italy. Invited speaker; October 2016.
- Novel insights into Parkinson's disease through iPSC-based technology. 9th Guangzhou International Conference on Stem Cell and Regenerative Medicine, Guangzhou, China. Invited speaker; December 2016.
- La nueva anticoagulación en la prevención del ictus. ¿Qué sabemos y qué desconocmeos? XXIX Escola de Fonseca (Seminario de investigación en neurociencias) – Instituto de Investigación Sanitaria de Santiago (IDIS) & Laboratorio de Investigación de Neurociencias Clínicas (LINC) & Servizo Galego de Saúde, Santiago de Compostela. Invited speaker; January 2017.
- Reprogramming somatic cell fate and identity: Biomedical applications. CABIMER Seminario de Investigación - Centro Andaluz de Biología Molecular & Medicina Regenerativa, Sevilla. Invited speaker; March 2017.
- Biomedical applications of somatic cell reprogramming. Bionand 2017 Conference Series, Málaga. Invited speaker; March 2017.
- Modelos avanzados de enfermedad humana. ¿En realidad son tan avanzados? XXX Escola de Fonseca (Seminario de investigación en neurociencias) – Instituto de Investigación Sanitaria de Santiago (IDIS) & Laboratorio de Investigación de Neurociencias Clínicas (LINC) & Servizo Galego de Saúde, Santiago de Compostela. Invited speaker; May 2017.
- Biomedical applications of induced reprogramming. Symposium of Romanian Society of Biochemistry and Molecular Biology – University of Medicine and Pharmacy "Victor Babes" Timisoara, Banat's University of Agricultural Aciences and Veterinary medicine "King Michael I of Romania" Timisoara and West University of Timisoara, Timisoara (Romania). Keynote speaker, Session chairman; June 2017.
- XXIV Jornada de Biologia Molecular - Societat Catalana de Biologia. Co-organizer, Session chairman; June 2017.
- Reprogramming, editing and gene therapy. 22nd European Hematology Association Congress - Pre-congress meeting: Molecular Aspects of Hematological Disorders, Madrid. Session chairman; June 2017.
- iPSC as a therapeutic tool. International Summer Course "Cell therapy from the bench to the bedside and return" from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2017.
- Industria farmacéutica: nuevos tratamientos basados en terapias avanzadas. XI Congreso de la Federación Española de Biotecnólogos (FEBiotec) | BAC León 2017, León. Invited speaker; July 2017.

- Regenerative Medicine. ETPN 2017 – 12th Annual Meeting (European Technology Platform), Málaga. Invited speaker; October 2017.
- Blade Runner: els humans i els replicants 2.0. Centre de Cultura Contemporània de Barcelona – CCCB Xmas Lectures: "Nadal de Blade Runner", Barcelona. Invited speaker; December 2017.
- Capturing disease complexity through reprogramming: The case of Parkinson's disease. Institut de Biologia Molecular de Barcelona – IBMB Xmas meeting 2017, Barcelona. Invited speaker; December 2017.
- Medicina regenerativa: present i futur & Cèl·lules mare: aplicacions biomèdiques, Invited speaker & Organizer, L'Hospitalet de Llobregat; January 2018
- Generation of cellular models of human rare diseases using gene editing. International Symposium: Applications of gene editing on research and therapy of human rare diseases – Fundación Ramón Areces, Madrid. Invited Speaker; January 2018
- Ciencias de la vida – El futuro del trabajo humano en la era digital. Mobile Week Barcelona (MWB) - mWeek talks- , Barcelona. Invited speaker; February 2018.
- Biotecnologia i medicina. "Està la Societat preparada per a l'edició genètica?" (Escola Europea d'Humanitats) Barcelona. Invited speaker; March 2018
- Disease modelling using iPSC. 9th Bienial Congress of the Spanish Society for Gene and Cell Therapy (SETGyC) Palma de Mallorca. Chair; March 2018
- Pluripotent stem cells and cell reprogramming. 9th Bienial Congress of the Spanish Society for Gene and Cell Therapy (SETGyC) Palma de Mallorca. Chair; March 2018
- Novel insights into Parkinson's disease through iPSC-based technology. 9th Bienial Congress of the Spanish Society for Gene and Cell Therapy (SETGyC) Palma de Mallorca. Invited speaker; March 2018
- Investigating human disease complexity through reprogramming-based approaches. IBV-CSIC Seminar series – Instituto de Biomedicina de Valencia; Valencia. Invited Speaker; June 2018
- iPSC as a therapeutic tool. International Summer Course "Cell therapy from the bench to the bedside and return" from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2018
- Lessons from Pluripotent Stem Cell Models. Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), Athens. Invited speaker; September 2018
- Biomedical applications of induced reprogramming to pluripotency. 2nd NMS Symposium on Chronic Diseases and Translational Science; Lisbon. Invited Speaker; October 2018
- Modeling Parkinson's Disease using iPSC. TerCel Annual Conference, Pamplona. Invited speaker; November 2018.
- iPSC-Based Modeling of Human Neurodegenerative Diseases: Possibilities, Trials and Tribulations. Symposium on "Stem Cell Science, Regenerative Medicine, Ethics and Society" (Universidade Nova de Lisboa and the Aga Khan University (AKU - Centre of Regenerative Medicine and Stem Cell Research)), Lisbon (Portugal). Invited speaker; June 2019.
- iPSC as a therapeutic tool. International Summer Course "Cell therapy from the bench to the bedside and return" from Universidad Internacional del Mar, Los Alcázares. Invited speaker; July 2019.
- Targeted genome engineering of iPSC for modeling complex human diseases. CIBER-BBN Annual Conference, Tarragona. Invited speaker; October 2019.
- 10th Biennial Congress of the Spanish Society for Gene and Cell Therapy (SETGyC), jointly organised with the ESGCT 27th Annual Congress, Barcelona. Co-organizer and Co-chair Opening Session; October 2019.
- Poniendo luz en la confusión. El desmadre de las células madre. Clarificación científica y terminológica en aras de su correcta aplicación en la medicina actual y de futuro. XV Jornada anual "El Dolor es Evitable" - Fundación Valenciana de Estudios Avanzados (FVEA), Valencia. Invited speaker; November 2019.
- L'edició en cèl·lules somàtiques. Aplicacions terapèutiques. Secció de Ciències Biològiques. Institut d'Estudis Catalans, Barcelona. Invited speaker; December 2019.
- Modeling (some of) the complexity of human diseases with cell-based systems. IDIBAPS Seminar, Barcelona. Invited speaker; September 2021.
- Cáncer hereditario y un nuevo modelo experimental basado en células madre. Associació Coordinadora Viladecans contra el càncer, Viladecans. Invited speaker; October 2021.

- ¿Son útiles las quimeras humano-animal para la medicina regenerativa? Debate “Quimeras Hombre-Mono: Mito, realidad y bioética”. Real Academia Europea de Doctores (RAED), Barcelona. Invited speaker; October 2021.
- Identifying genetic modifiers of human disease with iPSC-based systems. CEDOC Seminar. NOVA Medical School, Universidade Nova de Lisboa. Invited speaker; February 2022.
- Medicina Regenerativa. 3rd Biotechnology World Symposium and 4º Congreso Estudiantil de Ingeniería Biotecnológica SEIBT, Mazatlán, Mexico. Keynote speaker; October 2022
- ¿Qué son las células madre pluripotentes inducidas (iPS) y como nos ayudan a entender el funcionamiento del músculo cardiaco en las miocardiopatías? XI Jornada de Cardiogenética. HCU Virgen de la Arrixaca, Murcia. Invited speaker; November 2022
- The path to clinical translation of induced reprogramming technologies. 9th Annual Meeting ProRegEM, NOVA Medical School, Lisbon. Invited speaker; December 2022